Indolin-2-one and 1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives

Abstract

The present invention is concerned with indolin-2-one and 1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives of general formula I wherein Ar 1 , A 2 , R 1 , R 2 , R 3 , X and n are as described herein and pharmaceutically acceptable salts thereof for treatment of central nervous system disorders

We claim: 
     
       1. A compound of formula (I) 
       
         
           
           
               
               
           
         
         wherein 
         Ar 1  is phenyl, pyridinyl or pyrimidinyl; 
         Ar 2  is selected from the group consisting of (i), (ii) and (iii) 
       
       
         
           
           
               
               
           
         
         R 1  is hydrogen, C 1-7 -alkyl, halogen or C 1-7 -alkoxy; 
         R 3  is hydrogen, C 1-7 -alkyl, C 1-7 -alkyl substituted by hydroxy, cycloalkyl, oxetan-3-yl, pyridinyl, imidazolyl, pyrazolyl, pyrimidinyl, which rings may optionally substituted by C 1-7 -alkyl, or is —(CH 2 ) 3 —S(O) 2 -cyclopropyl; 
         X is CH or N; 
         n is 1 or 2; or, 
         or, a pharmaceutically acceptable salt thereof, a racemic mixture, an enantiomer, an optical isomer, a stereoisomer thereof. 
       
     
     
       2. The compound of  claim 1  wherein said compound is of formula Ia 
       
         
           
           
               
               
           
         
       
     
     
       3. The compound of  claim 1  wherein said compound is of formula Ib 
       
         
           
           
               
               
           
         
       
     
     
       4. The compound of  claim 1  wherein said compound is of formula Ic 
       
         
           
           
               
               
           
         
       
     
     
       5. The compound of  claim 1  which compounds are selected from the group consisting of:
 1,3,3-Trimethyl-6-(4-(pyridin-4-yl)-1H-pyrazol-1-yl)indolin-2-one; 
 1,3,3-Trimethyl-6-(4-(pyridin-3-yl)-1H-pyrazol-1-yl)indolin-2-one; 
 3,3-Dimethyl-1-(oxetan-3-yl)-6-(4-(pyridin-3-yl)-1H-pyrazol-1-yl)indolin-2-one; 1,3,3-Trimethyl-6-(2-(pyridin-3-yl)oxazol-4-yl)indolin-2-one; 
 3,3-Dimethyl-1-(oxetan-3-yl)-6-(4-(pyridin-4-yl)-1H-pyrazol-1-yl)indolin-2-one; 
 1,3,3-Trimethyl-6-(1-(pyridin-4-yl)-1H-pyrazol-4-yl)indolin-2-one; 
 1,3,3-Trimethyl-6-(1-(pyridin-3-yl)-1H-pyrazol-4-yl)indolin-2-one; 
 3,3-Dimethyl-6-(4-(pyridin-3-yl)-1H-pyrazol-1-yl)indolin-2-one; 
 1-Cyclopropyl-3,3-dimethyl-6-(4-(pyridin-3-yl)-1H-pyrazol-1-yl)indolin-2-one; 
 1,3,3-Trimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol-1-yl)indolin-2-one; 
 1-Cyclopropyl-3,3-dimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol-1-yl)indolin-2-one; 
 1,3,3-Trimethyl-6-(5-(pyridin-4-yl)-1H-pyrazol-3-yl)indolin-2-one; 
 3,3-Dimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol-1-yl)indolin-2-one; 
 1,3,3-Trimethyl-6-(5-(2-methylpyridin-4-yl)-1H-pyrazol-3-yl)indolin-2-one; 
 1,3,3-Trimethyl-6-(5-(pyridin-3-yl)-1H-pyrazol-3-yl)indolin-2-one; 
 1-Ethyl-3,3-dimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol-1-yl)indolin-2-one; 
 1,3,3-Trimethyl-6-(4-(6-methylpyridin-3-yl)-1H-pyrazol-1-yl)indolin-2-one; 
 1-Cyclopropyl-3,3-dimethyl-6-(4-(6-methylpyridin-3-yl)-1H-pyrazol-1-yl)indolin-2-one; 
 3,3-Dimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol--yl)-1-(oxetan-3-yl)indolin-2-one; 
 1,3,3-Trimethyl-6-(5-(6-methylpyridin-3-yl)-1H-pyrazol-3-yl)indolin-2-one; 
 1,3,3-Trimethyl-6-(1-methyl-5-(2-methylpyridin-4-yl)-1H-pyrazol-3-yl)indolin-2-one; 
 1,3,3-Trimethyl-6-(4-methyl-3-(2-methylpyridin-4-yl)-1H-pyrazol-5-yl)indolin-2-one; 
 a pharmaceutically acceptable salt thereof. 
 
     
     
       6. A pharmaceutical composition comprising a compound in accordance with  claim 1  and at least one pharmaceutically acceptable carrier, diluent or excipient for treating therapeutically active carrier for the treatment of certain central nervous system disorders which are positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, autism, Parkinson's disease, chronic pain, borderline personality disorder, sleep disturbances, chronic fatigue syndrome, stiffness, antiinflammatory effects in arthritis and balance problems.